Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Kymera Therapeutics and keeping the price target at $134.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Fein has given his Buy rating due to a combination of factors related to both clinical execution and strategic positioning. He emphasizes that Gilead’s recent option exercise on another Kymera program supports the strength of the company’s protein degradation platform, while KT-621’s Phase 2b trial is progressing on schedule with a design intended to robustly differentiate active doses from placebo.
Fein also highlights the substantial commercial potential of KT-621 in severe atopic dermatitis patients who have failed topical treatments but are not using biologics, underscoring the appeal of an oral alternative even with slightly lower efficacy. In addition, the asthma study is structured to efficiently generate dupilumab-like lung function data in a biomarker-enriched population, which could justify moving directly into a longer Phase 3 trial, and management’s reluctance to partner core assets at this stage further reinforces his conviction in the long-term value of the pipeline.
In another report released on March 27, TipRanks – Google also upgraded the stock to a Buy with a $91.00 price target.